Objective To determine test characteristics of provider judgment for empiric antibiotic provision to patients undergoing testing for a sexually transmitted infection.
C hlamydia trachomatis (CT) is the most commonly reported sexually transmitted infection in the United States, and prevalence of Neisseria gonorrhoeae (GC) and CT is highest among people age 25 years and younger. 1, 2 Although adolescents comprise 25% of the sexually active population, they account for 50% of all sexually transmitted infections annually. 3 Adolescent youth who seek care in hospital emergency departments (EDs) may be at even higher risk for infection because they represent a high-risk and vulnerable population. In fact, studies in pediatric ED settings have demonstrated GC and/or CT infection prevalence ranging from 5% in asymptomatic patients to 20%-28% in symptomatic patients. [4] [5] [6] [7] [8] Timely and appropriate treatment of GC and CT is important to reduce the risk of complications and transmission to sexual partners. Potential complications in women include pelvic inflammatory disease, infertility, ectopic pregnancy, chronic pain, and increased risk of HIV transmission. 2 In 1 study of patients returning for CT treatment after positive screening tests, 23% of women and 71% of men developed clinical cervicitis or urethritis in the interval between screening and treatment (median elapsed time, 13 days). Two women (1.7%) developed pelvic inflammatory disease within 1 month of positive screening for CT and/or GC. 9 Test results for GC and CT may return several days after the initial visit, and studies have shown loss to follow-up rates for untreated adolescents with positive GC/CT test results ranging from 31% to 43%. 7, 8 Given the high GC/CT prevalence in adolescent age groups and the lack of same-day test results, the Centers for Disease Control and Prevention (CDC) recommend empiric (presumptive) treatment for GC and CT for patients under 25 years of age who have clinical cervicitis or urethritis. 10 Although GC and CT tests are generally ordered from the ED to evaluate patients with symptoms or an increased risk of sexually transmitted infections, studies have shown that not all adolescents seen in the ED receive empiric treatment when testing is sent. Two studies in pediatric EDs found rates of empiric treatment of 39% and 70% for adolescents with testing sent. 7 We report the test characteristics of provider decision making for presumptive treatment of GC/CT in a larger sample population seen in the pediatric ED. Furthermore, we examined the association between patient demographics and chief complaint with the likelihood of empiric treatment and positive GC/CT test results. We also determined the test characteristics of provider judgment in subgroups of patients with different presenting complaints.
Methods
We performed a retrospective, cross-sectional review of the electronic health records for all adolescent visits to the pediatric ED of an urban, academic children's hospital from January through December 2012. We included all encounters with patients aged 13-19 years with both GC and CT testing sent from the ED. Encounters were excluded from the analysis if GC and CT were not both ordered, if either GC or CT test results were not documented, if the encounter was known to be related to a sexual assault, or if the patient was admitted to the hospital or transferred to another facility after the ED visit.
Patient demographics, chief complaint, provider information, medications administered or prescribed in the ED, and GC/CT test results were obtained from the medical record. Patient demographics included age, race, ethnicity, sex, and insurance type. We analyzed age as a continuous variable. Race/ ethnicity was defined as non-Hispanic black, non-Hispanic white, Hispanic, other, or unknown. We categorized insurance as private or nonprivate. Nonprivate insurance included patients with public insurance, other governmental insurance, no insurance, or missing insurance information. We categorized chief complaints as related to a sexually transmitted infection or not related to a sexually transmitted infection. Chief complaints involving request for sexually transmitted infection or pregnancy testing, lower abdominal/pelvic pain for females, vaginal or penile discharge, urinary symptoms, vaginal bleeding, testicular symptoms, or other genitourinary complaints were categorized as potentially sexually transmitted infection related. Provider type was determined by the most senior clinician and was categorized as either physician (including fellowship-trained pediatric emergency medicine physicians, general pediatricians, and other pediatric subspecialty physicians), nurse practitioner, physician assistant, or unknown/unavailable. Using the 2010 CDC Sexually Transmitted Disease Treatment guidelines, 10 we defined empiric treatment as receiving any combination of ceftriaxone, cefixime, azithromycin, or doxycycline.
GC/CT test results were considered the reference standard for comparison with provider decision to provide empiric treatment for a sexually transmitted infection. Our institution uses a polymerase chain reaction assay (Abbott RealTime PCR, Abbott Park, Illinois) for the detection of GC/CT from cervical, urethral, or urine samples. This assay has a reported sensitivity and specificity of 95.2% and 99.3% for CT and 97.5% and 99.7% for GC. 11, 12 In our ED, specimens that are sent for both GC and CT testing generally are obtained from urine, cervical, or urethral sites.
Data were entered into REDCap (Research Electronic Data Capture, developed at Vanderbilt University and hosted by Children's National Medical Center), a secure, web-based application designed to support data capture for research studies. 13 We used SPSS (version 22; IBM Corp, Armonk, New York) and SAS (version 9.3, SAS Institute Inc, Cary, North Carolina) for data analysis. We performed c 2 tests and bivariable logistic regression to examine relationships between patient demographic variables and the provision of empiric treatment for a sexually transmitted infection. We then performed multivariable logistic regression to identify factors associated with empiric treatment for sexually transmitted infections. Variables with P < .2 were included in our multivariable model. We calculated test characteristics for provider judgment for empiric treatment for a sexually transmitted infection by comparing provision of treatment for a sexually transmitted infection with GC/CT results. We then calculated these test characteristics in subgroups of patients by chief complaints (sexually transmitted infection-related vs not a sexually transmitted infection-related chief complaint). We used the Pearson c 2 test for statistical comparisons between sensitivities and specificities in different chief complaint subgroups.
The hospital's Institutional Review Board approved this study.
Results
There were 1223 ED visits that met inclusion criteria and were analyzed ( Figure) . The majority of our study sample was female (84.1%), nonprivately insured (86.6%), and of non-Hispanic black race/ethnicity (83.8%), with a median age of 17.2 years (IQR, 16.0-18.0). Most of the providers were physicians who had completed a pediatric residency, with or without subspecialty fellowship training (96.1% of encounters). The provider was a nurse practitioner in 46 encounters (3.8%) and a physician assistant in 2 encounters (0.2%). There was trainee involvement in 57.4% of encounters. 
Figure.
Study population diagram of adolescents tested for GC and CT.
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Patients Receiving Empiric Treatment
Empiric antibiotics were administered in 615 of the 1223 encounters (50.3%). In bivariable analyses (Table I) , male sex, non-Hispanic race/ethnicity, older age, nonprivate insurance status, and encounters involving a nurse practitioner were associated with an increased likelihood of empiric treatment. Patients with potentially sexually transmitted infection-related chief complaints were also more likely to receive empiric treatment compared with those with non-sexually transmitted infection-related complaints. Trainee involvement in the visit was not associated with provision of empiric treatment. In the multivariable model, sex, race/ethnicity, insurance status, chief complaint, and provider type were all associated with empiric treatment for a sexually transmitted infection ( Table I) .
Prevalence of Positive GC/CT Tests
The overall prevalence of infection with either GC and/or CT in our sample was 23.2% (18.8% CT, 7.3% GC, and 2.9% coinfection) ( Table II) . The prevalence was 34% for male adolescents (22.7% CT, 17.0% GC, and 5.7% coinfection) and 21.2% for female adolescents (18.1% CT, 5.4% GC, 2.3% coinfection). The prevalence of GC and/or CT infection was higher among non-Hispanic black patients (24.9%; n = 1025) than in the smaller subgroups of Hispanic patients (5.9%; n = 85) and non-Hispanic white patients (0%; n = 9 Patients who tested positive for GC and/or CT had increased odds of receiving empiric treatment (OR, 2.55; 95% CI, 1.92-3.37). Among those patients who tested positive for a sexually transmitted infection, those with CT only were less likely to receive empiric antibiotics than those with either GC only or coinfection (0.54; 95% CI, 0.31-0.95). Table II shows the performance characteristics of provider judgment for provision of empiric treatment for a sexually transmitted infection compared with sexually transmitted infection test results. Provider judgment for empiric treatment for a sexually transmitted infection had a sensitivity of 67.6% (95% CI, 61.8-73.0) and specificity of 55.0% (95% CI, 51.7-58.2). With a 23.2% prevalence of sexually transmitted infections, provider judgment for empiric treatment had a positive predictive value of 31.2% (95% CI, 27.6-35.0) and a negative predictive value of 84.9% (95% CI, 81.8-87.6).
Performance Characteristics of Provider Judgment
Ninety-two of the 284 patients (32.4%) who ultimately tested positive for a sexually transmitted infection did not receive empiric treatment, and 423 of the 939 patients (45%) who tested negative for a sexually transmitted infection were treated empirically. For the remaining 708 patients (57.9% of the total sample), provider judgment regarding empiric antibiotic treatment was in agreement with the test results.
Among patients presenting with possible sexually transmitted infection-related chief complaints, provider judgment for empiric antibiotics had a higher sensitivity (71% vs 55%; P = .02) but lower specificity (52% vs 67%; P < .01) compared with patients with non-sexually transmitted infectionrelated complaints. We also examined provider performance characteristics for subgroups of chief complaints (Table III) .
Antibiotic Selection
Of the 615 patients who received empiric treatment for a sexually transmitted infection, 558 (90.7%) were treated with antibiotic regimens that complied with the 2010 CDC Sexually Transmitted Disease treatment guidelines, including appropriate doses of ceftriaxone plus azithromycin, ceftriaxone plus doxycycline, cefixime plus azithromycin, cefixime plus doxycycline, or azithromycin alone at dosing for penicillin and cephalosporin-allergic patients. Another 8.9% (n = 55) received treatment that was not in compliance with the 2010 CDC Sexually Transmitted Disease Treatment Recommendations, including monotherapy with azithromycin (n = 20), monotherapy with ceftriaxone (n = 5), inappropriate dosing with ceftriaxone 125 mg (n = 29), or inappropriate dosing of azithromycin (n = 1). For the remaining 0.3% of empirically treated patients (n = 2), ceftriaxone and azithromycin were given, but the dosing could not be determined.
Discussion
This retrospective, single-center study found that the sensitivity and specificity of provider judgment for provision of empiric treatment for GC/CT was low. Almost one-third of patients who tested positive for a sexually transmitted infection were not treated empirically. Furthermore, almost onehalf of those patients who tested negative for a sexually transmitted infection were treated empirically. A lack of sensitivity results in delays in treatment and risks loss to followup without treatment, and poor specificity suggests unnecessary exposure to antibiotics. Our results are similar to the findings of Pattishall et al of low sensitivity and specificity of provider judgment to detect GC/CT in a pediatric ED. However, in our sample, the sensitivity was higher and specificity was lower than Pattishall's sample, suggesting an overall lower threshold for empiric treatment in our study population. In the sample from Pattishall et al, only 39% of adolescents who underwent testing received empiric treatment, and 41% of those with positive tests did not receive treatment at the initial visit. 8 In part, differences in provider decision making for empiric treatment may be related to local disease prevalence, although the prevalence of GC and/or CT in their study was 28%. The prevalence of GC and/or CT infection of 23.2% in our study is consistent with previous reported prevalence among symptomatic adolescents seeking care at a pediatric ED (20%-28%). [6] [7] [8] Provider judgment for treatment in the subgroup of patients presenting with potentially sexually transmitted infectionrelated chief complaints (including females with abdominal or pelvic pain) was 71% sensitive and 52% specific. Not surprisingly, this suggests that providers have a lower threshold for presumptive treatment when caring for patients who manifest with symptoms that may be related to a sexually transmitted infection compared with patients presenting with non-sexually transmitted infection-related chief complaints, where provider judgment had 55% sensitivity and 67% specificity. However, current CDC guidelines recommend empiric treatment for all patients presenting with sexually transmitted infection-related symptoms. Therefore, our data suggest a role for provider education to increase presumptive treatment for a sexually transmitted infection in patients presenting with related symptoms. If all patients with sexually transmitted infection-related symptoms had received empiric treatment, an additional 65 patients would have been treated appropriately for infection at the time of the visit and an additional 382 uninfected patients would have received antibiotics. Consequently, increased empiric treatment for symptomatic patients would have improved sensitivity while decreasing specificity. In areas of high sexually transmitted infection prevalence, the public health benefit of earlier treatment and decreased loss to follow-up care may justify this tradeoff.
Provider judgment for the subset of patients with abdominal and/or pelvic pain was 58% sensitive and 60% specific, suggesting a similar threshold for empiric antibiotics as that seen for patients with nonspecific chief complaints. Although the differential diagnosis of abdominal pain may be broader than the differential diagnosis in patients with specific sexually transmitted infection concerns or gynecologic complaints, it remains important to consider sexually transmitted infection for this subgroup of patients, as illustrated by the fact that testing was sent for these patients. It is difficult to know whether the rate of empiric treatment in this subset was influenced by additional clinical details or by provider perceptions of risk. Nurse practitioner encounters were more likely to involve empiric treatment than physician encounters, suggesting possible differences in training, but the generalizability of this finding is limited by the relatively small number of nurse practitioners in our sample.
Our analysis found that patient sex, age, race/ethnicity, insurance status, and chief complaint were all associated with the provider's decision to administer empiric antibiotics. The prevalence of GC and/or CT infection was lower in the nonHispanic white and Hispanic subgroups, but the odds of empiric treatment were higher for non-Hispanic white patients and lower for Hispanic patients compared with nonHispanic black patients. Our ability to evaluate racial/ethnic differences was limited because most of the patients with testing ordered were non-Hispanic black or Hispanic race/ethnicity. Goyal et al 14 examined symptomatic adolescent patients in a pediatric ED and found that patients of black or African American race were more likely to have testing for a sexually transmitted infection sent, and thus patients of other racial/ ethnic groups may be underrepresented in our sample. Prior studies have shown a higher prevalence of GC/CT in patients of non-Hispanic black race/ethnicity, although it is not clear if these data reflect differences in exposure or more limited access to healthcare for screening and treatment. 1, 2, 5 Given the high prevalence of GC/CT in adolescents and the barriers to follow-up, providers should consider strongly treatment for patients who have clinical indications for testing, regardless of race/ethnicity.
Although older patients and patients with nonprivate insurance in our sample were more likely to receive empiric antibiotics, there was no difference in GC/CT prevalence by age or insurance status, suggesting providers' threshold to treat younger and privately insured patients empirically may be too high and providers may be missing infections owing to bias or assumptions about patient follow-up. Inadequate empiric treatment in certain demographic subgroups results in delays in treatment and risks loss to follow-up, and will result in maintaining the relatively high infection prevalence observed in our sample and our local community. The ED frequently serves as a safety net provider for patients who lack access to primary care. The ED may also provide an alternative for adolescents followed by pediatricians who do not provide routine gynecologic care in the office, and for adolescents who are uncomfortable discussing sexual health and behaviors with their primary provider.
Although male patients made up only 15.7% of the encounters in which GC/CT testing was performed, they were more likely to receive empiric treatment and more likely to have positive test results. Providers may be less likely to order testing for a sexually transmitted infection for male adolescents, and male patients who undergo testing may be more likely to have clinical evidence of urethritis, prompting empiric treatment. The prevalence of GC/CT among males in our sample was lower than reported elsewhere in the literature. Timm et al 15 found that 64% of males age 15-21 years seeking care at a pediatric ED with concern for a sexually transmitted infection or a genitourinary complaint were positive for GC or CT.
In our sample, almost one-third of adolescents with GC/ CT were discharged without antibiotics and almost one-half of those with negative tests received presumptive antibiotics. Possible strategies to minimize both loss to follow-up and delays in treatment, as well as overuse of antibiotics, include improving follow-up mechanisms, developing clinical decision rules for the use of empiric antibiotics, and point-of-care testing for GC/CT in the pediatric ED. 7, 8, [16] [17] [18] Our study has some limitations. The study encompassed 1 year of patient visits to a single pediatric ED, and may not be generalizable to all practice settings, groups of providers, or patient populations. Data for this study were obtained retrospectively and rely on the integrity of the medical record. We do not have information on provider intent, so it is possible that some patients receiving antibiotic combinations inconsistent with the CDC sexually transmitted infection guidelines were not being treated for a sexually transmitted infectionrelated infection. It is also possible that the treating provider may have had access to information that is not apparent to us, such as recent treatment for sexually transmitted infection, known exposures, or patient refusal to take empiric antibiotics. Furthermore, although we did have access to the chief complaint documented in triage, we did not have specific information on sexually transmitted infection symptoms for each patient.
Provider judgment to administer empiric treatment for CT and GC infections lacks sensitivity and specificity. Future steps should better define indications for empiric treatment in highrisk populations and seek to develop accurate point-of-care testing for these infections. ■
